Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics

Published:2020-01-11 Issue:2 Volume:16 Page:207-228
ISSN:1744-666X
Container-title:Expert Review of Clinical Immunology
language:en
Short-container-title:Expert Review of Clinical Immunology

Author:

Chiu Ying-Ming¹²,Chen Der-Yuan¹²³⁴⁵

Affiliation:

1. Rheumatology and Immunology Center, China Medical University Hospital, Taichung, Taiwan

2. College of Medicine, China Medical University, Taichung, Taiwan

3. Translational Medicine Laboratory, Rheumatic Diseases Research Center, China Medical University Hospital, Taichung, Taiwan

4. Program in Translational Medicine and Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung, Taiwan

5. Institute of Biochemistry, Microbiology and Immunology, Chung Shan Medical University, Taichung, Taiwan

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/1744666X.2019.1705785

Reference250 articles.

1. Cytokine Pathways and Joint Inflammation in Rheumatoid Arthritis

2. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases

3. Rheumatoid arthritis pathophysiology: update on emerging cytokine and cytokine-associated cell targets

4. Treatment of rheumatoid arthritis: state of the art 2009

5. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic potential of natural alkaloid emetine against emerging COVID-19 and future viral pandemics;European Journal of Medicinal Chemistry Reports;2024-12

2. Safety assessment of sulfasalazine: a pharmacovigilance study based on FAERS database;Frontiers in Pharmacology;2024-09-12

3. Quantification of longitudinal patient-reported burden of adverse drug reactions attributed to the use of TNF-α inhibitors in inflammatory rheumatic diseases: an observational prospective cohort study;Expert Opinion on Drug Safety;2024-08-30

4. Comparisons of infection events associated with tumor necrosis factor inhibitors in patients with inflammatory arthritis: A systematic review and network meta-analysis;Frontiers in Pharmacology;2024-07-11

5. Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review;European Journal of Cancer;2024-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3